ReviewClinical cardiology2017
PCSK9 inhibitor access barriers-issues and recommendations: Improving the access process for patients, clinicians and payers.
Review in Clinical cardiology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 48 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
48 citing papers in PubMed.
- Potential Cardiovascular Events Avoided with Bempedoic Acid Plus Ezetimibe Fixed-Dose Combination Compared with Ezetimibe Alone in Patients with Atherosclerotic Cardiovascular Disease Taking Maximally Tolerated Statins.American journal of cardiovascular drugs : drugs, devices, and other interventions · 2023Trial
- Review
- Adherence to PCSK9 Inhibitors in Clinical Practice: Systematic Review and Meta-Analysis of Observational Studies.JACC. Advances · 2026Article
- Barriers and Facilitators to the Use of Novel Injectable Lipid-Lowering Therapies in Patients with Dyslipidemia or Cardiovascular Disease: A Scoping Review.Medicina (Kaunas, Lithuania) · 2026Article
- Effect of Early Initiation of Evolocumab on Lipid Profiles Changes in Patients With Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention.Korean circulation journal · 2026Article
- PCSK9 inhibitors patterns of use in France from nationwide repeated cross-sectional and cohort studies.Scientific reports · 2026Article
- Safety and Efficacy of Achieving Very Low LDL Cholesterol Concentrations with PCSK9 Inhibitors.Journal of clinical medicine · 2025Review
- Review
- Therapeutic Inertia in Dyslipidemia Management for Secondary Cardiovascular Prevention: Results from the Italian ITACARE-P Network.Journal of clinical medicine · 2025Article
- Impact of manufacturer-initiated list price reduction on patient out-of-pocket costs forJournal of managed care & specialty pharmacy · 2024Article
- The Hurdle of Access to Emerging Therapies and Potential Solutions in the Management of Dyslipidemias.Journal of clinical medicine · 2024Review
- Age- and sex-based heterogeneity in coronary artery plaque presence and burden in familial hypercholesterolemia: A multi-national study.American journal of preventive cardiology · 2024Article
- Trends in Patient Access to and Utilization of Prescribed PCSK9 Inhibitors in a Large US Claims Database From 2015 to 2021.Circulation. Cardiovascular quality and outcomes · 2024Article
- Challenges in the management of familial hypercholesterolemia: a case report.Frontiers in cardiovascular medicine · 2024Article
- Reduction of biologic pricing following biosimilar introduction: Analysis across 57 countries and regions, 2012-19.PloS one · 2024Article
- A virus-like particle-based bivalent PCSK9 vaccine lowers LDL-cholesterol levels in non-human primates.NPJ vaccines · 2023Article
- Gaps in Guideline-Based Lipid-Lowering Therapy for Secondary Prevention in the United States: A Retrospective Cohort Study of 322 153 Patients.Circulation. Cardiovascular quality and outcomes · 2023Article
- A Virus-like particle-based bivalent PCSK9 vaccine lowers LDL-cholesterol levels in Non-Human Primates.bioRxiv : the preprint server for biology · 2023Article
- President's page: The re-emergence of prevention in the forefront of cardiology.American journal of preventive cardiology · 2023Article
- Impact of list price changes on out-of-pocket costs and adherence in four high-rebate specialty drugs.PloS one · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The proprotein convertase subtilisin/kexin type 9 inhibitors or monoclonal antibodies likely represent the greatest advance in lipid management in 30 years. In 2015 the US Food and Drug Administration approved both alirocumab and evolocumab for high-risk patients with familial hypercholesterolemia (FH) and clinical atherosclerotic cardiovascular disease requiring additional lowering of low-density lipoprotein cholesterol. Though many lipid specialists, cardiovascular disease prevention experts, endocrinologists, and others prescribed the drugs on label, they found their directives denied 80% to 90% of the time. The high frequency of denials prompted the American Society for Preventive Cardiology (ASPC), to gather multiple stakeholder organizations including the American College of Cardiology, National Lipid Association, American Association of Clinical Endocrinologists (AACE), and FH Foundation for 2 town hall meetings to identify access issues and implement viable solutions. This article reviews findings recognized and solutions suggested by experts during these discussions. The article is a product of the ASPC, along with each author writing as an individual and endorsed by the AACE.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.